Skip to main content

HIV Drugs Market to Exhibit 6.1 % CAGR; Growing Emphasis on Research and Development of Efficient Drugs to Enable Growth, says Fortune Business Insights

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, June 08, 2020 (GLOBE NEWSWIRE) — The global HIV Drugs Market is likely to derive growth form the increasing prevalence of the disease across the world. According to a report published by Fortune Business Insights, titled “HIV Drugs Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 25,314.0 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 40,675.0 Mn by 2026, thereby exhibiting a CAGR of 6.1% in the forecast periodThe emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.Please visit: https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115
The increasing emphasis on the research and development of HIV/AIDS drugs has led to several drug innovations in recent years. The increasing demand for therapeutic procedures and treatment methods has created a subsequent emphasis on the development of related drugs. Fortune Business Insights has predicted that the increasing emphasis on HIV/AIDS treatment will encourage regulatory authorities to approve the usage of proposed drugs.Fortune Business Insights has identified growing regulatory approvals as one of the primary growth stimulators that have constituted a substantial amount of global HIV Drugs Market value in recent years. In April 2019, the Food and Drug Administration (FDA) passed an approval for the Dovato, a drug aimed at treatment of treatment of HIV-1 in patients with no antiretroviral (ARV) treatment history.In June 2018, the Food and Drug Administration passed an approval for Merck’s Delstrigo for the treatment of HIV-1. Fortune Business Insights has predicted that major drug approvals will have a direct impact on the global HIV Drugs Market in the forthcoming years. The report encompasses several drug approvals of recent years.The rising prevalence of HIV/AIDS has resulted in increasing emphasis on the development of treatment methods and drugs associated with the treatment of this disease. According to data published by the Joint United Nations Program in 2018, around 37.9 million people in the world are diagnosed with HIV/AIDS. Among the 37.9 million people, around 23.3 million people were undergoing antiretroviral therapy.Due to the increasing incidence of HIV/AIDS across the world, the HIV/AIDS drugs companies have witnessed massive growth opportunities in recent years. The large patient pool will offer a huge potential for growth of several companies in the market, which in turn, will have a direct impact on the global HIV Drugs Market in the forthcoming years. The report includes several factors that constituted an increase in the global HIV/AIDS market value in recent years.ViiV HealthcareGilead Sciences, Inc.Merck Sharp & Dohme Corp.Bristol-Myers Squibb CompanyJanssen Pharmaceuticals, Inc.Theratechnologies Inc.Mylan Pharmaceuticals Inc.Genentech, Inc.AbbVie Inc.IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsEpidemiology of HIV/AIDS by Key CountriesOverview of Pipeline AnalysisRegulatory Scenario by Key CountriesPricing AnalysisKey Strategies Employed by Market Leaders in Various RegionsOverview of New Product LaunchesGlobal HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis, Insights and Forecast – By Drug ClassNon-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)Integrase InhibitorsCombination HIV MedicinesOthersMarket Analysis, Insights and Forecast – By Distribution ChannelHospital PharmaciesRetail PharmaciesOnline PharmaciesOthersMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificRest of WorldTOC Continued….!!!

Have a Look at Related Reports:Hospital Acquired Infections Treatment Market Size, Share and Global Trend By Infection Type (Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections), By Treatment (Antibacterial, Antiviral, Antifungal), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026Infectious Disease Molecular Diagnostics Market Size, Share and Global Trend By Technology (Mass Spectroscopy, Capillary Electrophoresis, Next Generation Sequencing, Chips & Microarrays, In-Situ Hybridization), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV) Infection, Human Papillomavirus (HPV) Infection), By End User (Hospitals & Clinics, Diagnostic Centres, Research Institutes) and Geography Forecast till 2026Diagnostic Antibodies Market Size, Share and Global Trend By Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies), Application (Hepatitis Diagnostics, Tuberculosis Diagnostics, Cancer Diagnostics, Oncology Diagnostics, HIV Diagnostics, Infectious Disease Diagnostics) End User (Hospitals, Diagnostic Centres) and Geography Forecast till 2026Protease Inhibitors Market Size, Share and Global Trend, By Disease Indication (HIV/AIDS,Hepatitis C,Alpha-1 Antitrypsin Deficiency,Hereditary Angioedema (HAE),Others), By Distribution Channel (Hospitals pharmacies,Retail pharmacies,Online pharmacies),and Geography Forecast till 2026About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/hiv-aids-drugs-market-9223

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.